Press release
Cancer Cachexia Market Size, Share and Growth Report, 2034
Cancer Cachexia Market
The Cancer Cachexia Market focuses on a debilitating syndrome characterized by involuntary weight loss, muscle wasting, fatigue, and reduced appetite in cancer patients. It affects up to 80% of patients with advanced cancer, particularly those with lung, gastrointestinal, and pancreatic cancers.
Cancer cachexia significantly impacts quality of life, treatment tolerance, and overall survival. Traditionally underdiagnosed and undertreated, the condition is now receiving increasing attention due to growing awareness, improved screening tools, and the development of targeted pharmacological and nutritional interventions. The next decade will see integration of multimodal therapy, combining drug treatment, nutritional support, and physical activity regimens to manage symptoms effectively.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/70840
Market Overview
• Market Size 2024: USD 2.4 billion
• Forecast 2034: USD 4.1 billion
• CAGR (2024-2034): 5.6%
Key Highlights:
• Growing use of progestogens, corticosteroids, and novel anabolic agents.
• Expanding clinical research in ghrelin receptor agonists and anti-inflammatory agents.
• Increased recognition of cachexia as a treatable complication in oncology guidelines.
• Integration of nutritional and exercise programs into cancer care pathways.
Market Drivers:
• Rising global cancer incidence and advanced-stage diagnoses.
• Improved physician awareness and early intervention protocols.
• Development of targeted therapies with reduced toxicity compared to conventional options.
Market Challenges:
• Limited approved pharmacological treatments specifically for cachexia.
• Underreporting and underdiagnosis due to overlapping cancer symptoms.
• Low patient adherence to nutritional and exercise regimens in advanced disease stages.
Leading Players:
• Pfizer Inc.
• Merck & Co., Inc.
• Novartis AG
• Helsinn Healthcare SA
• AstraZeneca plc
• Bristol Myers Squibb (BMS)
• Eisai Co., Ltd.
• GTx, Inc.
• ONO Pharmaceutical Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
Segmentation Analysis
By Product
• Progestogens (e.g., Megestrol Acetate)
• Corticosteroids
• Ghrelin Receptor Agonists
• Anabolic Agents
• Nutritional Supplements
• Others (Anti-inflammatory Agents, Combination Therapy)
By Platform
• Pharmaceuticals
• Nutritional Products
• Rehabilitation Programs
By Technology
• Oral Drug Delivery
• Injectable Drug Delivery
• Enteral Nutrition Support
• Telehealth Monitoring Tools
By End Use
• Hospitals
• Specialty Oncology Clinics
• Home Care Settings
• Rehabilitation Centers
By Application
• Lung Cancer-Associated Cachexia
• Gastrointestinal Cancer-Associated Cachexia
• Pancreatic Cancer-Associated Cachexia
• Other Advanced Cancers
Segmentation Summary:
Pharmaceuticals currently dominate due to widespread use of progestogens and corticosteroids for appetite stimulation. However, ghrelin receptor agonists and anabolic agents are expected to drive the fastest growth, especially when combined with nutritional and rehabilitation programs.
Get Your Exclusive Offer with up to 10% Discount:
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=70840
Regional Analysis
North America
• Largest market share due to high cancer prevalence, advanced oncology infrastructure, and increasing physician education on cachexia management.
• U.S.-led clinical trials for novel drug candidates are expanding rapidly.
Europe
• Strong growth fueled by integrated cancer care systems and public reimbursement for nutritional support.
• Germany, France, and the UK dominate, with rising adoption of multimodal cachexia management strategies.
Asia-Pacific
• Fastest-growing market due to large patient population, increasing cancer diagnosis rates, and improving access to oncology care.
• Japan, China, and Australia lead in research collaborations and clinical adoption.
Middle East & Africa
• Gradual market penetration in urban oncology centers; rural areas face access limitations.
• Government-led cancer awareness campaigns are promoting early symptom recognition.
Latin America
• Brazil and Mexico expanding supportive care services for cancer patients.
• Private sector investment improving access to nutritional and pharmacological interventions.
Regional Trends Summary:
North America leads in innovation and early adoption, while Asia-Pacific offers the largest growth potential due to rising awareness, healthcare spending, and improved oncology services.
Market Dynamics
Key Growth Drivers
• Increasing global cancer burden leading to higher cachexia prevalence.
• Growing clinical trial activity for novel agents targeting muscle wasting and inflammation.
• Expansion of multidisciplinary care teams integrating oncology, nutrition, and physiotherapy.
Key Challenges
• Limited approved therapies for cachexia-specific treatment.
• Late-stage diagnosis reducing treatment effectiveness.
• Economic barriers to comprehensive cachexia management in low-income regions.
Latest Trends
• Development of ghrelin mimetics for appetite stimulation and weight gain.
• Integration of AI-driven monitoring tools to track muscle mass and nutrition status remotely.
• Clinical trials exploring combination regimens with anti-inflammatory and anabolic agents.
• Use of personalized nutrition plans based on genetic and metabolic profiling.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/70840/cancer-cachexia-report-cancer-cachexia-cc-market
Competitor Analysis
Major Players:
1. Pfizer Inc. - Oncology supportive care portfolio
2. Merck & Co., Inc. - Cancer supportive therapy research
3. Novartis AG - Targeted and supportive oncology drugs
4. Helsinn Healthcare SA - Anamorelin (ghrelin receptor agonist)
5. AstraZeneca plc - Oncology innovation programs
6. Bristol Myers Squibb - Immunotherapy and supportive care collaborations
7. Eisai Co., Ltd. - Nutritional and oncology supportive therapies
8. GTx, Inc. - Selective androgen receptor modulators (SARMs)
9. ONO Pharmaceutical Co., Ltd. - Cachexia drug research pipeline
10. Teva Pharmaceutical Industries Ltd. - Generic supportive care medications
Competitive Summary:
The market is moderately competitive, with Helsinn Healthcare leading in ghrelin agonist development. Major pharmaceutical companies are increasingly exploring combination approaches that integrate pharmacological, nutritional, and rehabilitative interventions.
Conclusion
The Cancer Cachexia Market is projected to grow from USD 2.4 billion in 2024 to USD 4.1 billion by 2034, at a CAGR of 5.6%. The next decade will see significant expansion in targeted therapy, nutritional intervention, and digital health integration for cachexia management.
This report is also available in the following languages : Japanese (がん性悪液質レポート がん性悪液質(CC)市場), Korean (암 악액질 보고서 암 악액질(CC) 시장), Chinese (癌症恶病质报告 癌症恶病质(CC)市场), French (Rapport sur le marché de la cachexie cancéreuse (CC)), German (Bericht über Krebskachexie Markt für Krebskachexie (CC)), and Italian (Rapporto sulla cachessia cancerosa Mercato della cachessia cancerosa (CC)), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/70840
Our More Report:
Ferritin ELISA Test Kit
https://exactitudeconsultancy.com/reports/65905/ferritin-elisa-test-kit-market
Prolactin ELISA Test Kit
https://exactitudeconsultancy.com/reports/65907/prolactin-elisa-test-kit-market
Beta-Human Chorionic Gonadotropin (HCG) ELISA Test Kit
https://exactitudeconsultancy.com/reports/65909/beta-human-chorionic-gonadotropin-hcg-elisa-test-kit-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cancer Cachexia Market Size, Share and Growth Report, 2034 here
News-ID: 4143789 • Views: …
More Releases from Exactitiude Consultancy
Non-Muscle Invasive Bladder Cancer Market Industry Analysis by Size, Share, Grow …
Introduction
The Non-Muscle Invasive Bladder Cancer (NMIBC) market is poised for significant growth as advancements in intravesical therapies, immuno-oncology drugs, and molecular diagnostics improve patient outcomes. NMIBC, which accounts for about 70-75% of all newly diagnosed bladder cancer cases, is characterized by high recurrence rates but relatively low mortality compared to muscle-invasive forms. The rising global prevalence, particularly among aging populations, is prompting greater investment in early diagnosis, novel drug delivery…
NK Cell Therapy Market Size And Global Industry Forecast 2034
NK Cell Therapy Market Outlook 2024-2034: Immuno-Oncology Innovation and Off-the-Shelf Therapies Set the Stage for Rapid Growth
Introduction
The Natural Killer (NK) Cell Therapy market is one of the most dynamic segments in immuno-oncology, driven by breakthroughs in cell engineering, off-the-shelf allogeneic therapies, and combination regimens with checkpoint inhibitors. NK cells, part of the innate immune system, have demonstrated strong potential in targeting and destroying cancer cells without prior sensitization, making them…
Neuroendocrine Prostate Cancer Market Size, Share and Growth Report, 2034
Introduction
The Neuroendocrine Prostate Cancer (NEPC) market is emerging as a key focus area in oncology due to its aggressive nature, poor prognosis, and increasing recognition as a distinct clinical entity. NEPC can develop de novo or as a treatment-emergent form of advanced prostate cancer following androgen deprivation therapy (ADT) resistance. While rare, NEPC is challenging to treat, requiring a combination of chemotherapy, targeted agents, and investigational therapies. Rising awareness, advancements…
Metastatic Colorectal Cancer Market Size And Global Industry Forecast 2034
Introduction
The Metastatic Colorectal Cancer (mCRC) market is entering a transformative phase as precision medicine, biomarker-driven treatment strategies, and immunotherapy reshape patient care. Increasing adoption of EGFR inhibitors, VEGF inhibitors, immune checkpoint inhibitors, and combination regimens is improving survival rates, while advancements in molecular diagnostics are enabling more tailored treatment approaches. Over the next decade, continuous R&D efforts and expanded access to innovative therapies are expected to drive market growth.
Download Full…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
